Timing of Shingles Vaccine After Acute Herpes Zoster
Patients can receive the shingles vaccine at least 2 months after an acute episode of herpes zoster, once the acute symptoms have resolved. 1
Recommended Waiting Period
Minimum interval: 2 months after the acute herpes zoster episode before administering either recombinant zoster vaccine (RZV/Shingrix) or live zoster vaccine (ZVL/Zostavax). 1
This 2-month minimum is based on documented evidence showing the shortest interval between an initial herpes zoster episode and recurrence is approximately 2 months. 1
The vaccine should be given after the acute stage has resolved and symptoms have abated. 1, 2
Rationale for Vaccination After Prior Herpes Zoster
Vaccination is strongly recommended even after a prior episode of shingles because:
Herpes zoster recurrence rates are substantial: cumulative incidence reaches 2.5% at 2 years, 6.6% at 6 years, and 10.3% at 10 years following an initial episode. 1
Both RZV (Shingrix) and ZVL (Zostavax) are recommended for patients with a history of herpes zoster to prevent recurrence. 1, 2
Vaccine Efficacy Considerations
The timing of vaccination (whether at 6-12 months versus 1-5 years post-infection) does not significantly impact immunogenicity:
A prospective study demonstrated that live zoster vaccine produced similar immune responses whether administered at 6-12 months or 1-5 years after acute herpes zoster. 3
Both time intervals showed significant increases in VZV IgG concentrations and T-cell responses following vaccination. 3
Preferred Vaccine Choice
RZV (Shingrix) is the preferred vaccine for adults aged ≥50 years, including those with prior herpes zoster:
RZV demonstrates 97.2% efficacy against herpes zoster in adults ≥50 years and 91.3% efficacy in adults ≥70 years. 4
The vaccine requires 2 doses administered 2-6 months apart for optimal protection. 4
Important Clinical Caveats
Do not use the vaccine to treat acute herpes zoster or to prevent postherpetic neuralgia in patients with active disease. 2
Patients do not need serologic testing for varicella immunity before vaccination. 1, 2
The vaccine is contraindicated in immunocompromised patients if using the live attenuated vaccine (ZVL), but RZV can be used in immunocompromised individuals aged ≥18 years. 1